Mr. Murdock is the co-founder of Panvaxal, LLC. He is also the Senior Vice President of Investments for Castle & Cooke, Inc., and a member of the Executive Board of Directors where he serves on both the audit and finance committees. Previously, he was a member of the Board of Directors of Dole Food Company, Inc. (NYSE: DOL) where he also served on the audit and finance committees. He was also Vice President of Mergers and Acquisitions for Pacific Holding Company, the operating group for the conglomerate of public and private companies owned by the Murdock family. Mr. Murdock is dedicated to the discovery, development and commercialization of novel cell-based therapeutic vaccines for the treatment of cancer. As member of the executive leadership team of Dole, he helped to conceive the Dole Nutrition Institute located at the North Carolina Research Campus in Kannapolis, North Carolina. Founded by the Murdock family in 2003, the DNI is a research and education center dedicated to improving human health through research into nutrition, agriculture and a plant-based diet to prevent chronic diseases such as cancer and diabetes.

Mr. Germain has been involved as a founder, director, chairman of the board of, and/or investor in, over twenty companies in the biotech field and assisted many of them in arranging corporate partnerships, acquiring technology or advisor to, entering into mergers and acquisitions, and executing financings and going public transactions. Among the companies he co-founded are Incyte Corporation, Neurocrine Biosciences, Inc., Alexion Pharmaceuticals, Inc., and ChromaDex, Inc. He graduated from New York University School of Law in 1975, Order of the Coif, and was a partner in a New York law firm practicing corporate and securities law before leaving in 1986. Since then, and until he entered the biotech field in 1991, he served in senior executive capacities, including as president of a public company that was sold in 1991. Mr. Germain is a Managing Director at The Aentib Group, a boutique merchant bank in New York. Mr. Germain also serves as an unpaid advisor to Caring Cross, the licensor of the company’s tri-specific CAR-T and two addition CAR-T product candidates. Mr. Germain serves as Chairman of the Board of Directors of Scinai Immunotherapeutics Ltd., a public company based in Israel focused on developing vaccines and treatments for infectious disease and related illness, and from 2009 through June 2022, as a member of the Board of Directors, and formerly Vice Chairman, of Pluristem Therapeutics Inc., also a public company based in Israel developing novel cell therapies.

Mr. Pernice is a seasoned leader and corporate executive with more than 25 years of experience working in the White House, C-Suites of Fortune 500 companies, and as an executive officer and advisor to the Family Offices of billionaire businessman David H. Murdock. A Presidential appointee in three White House Administrations, he served on the senior staff and was a diplomatic representative of the United States traveling to more than ninety-two countries. He was later appointed Senior Policy Advisor and Executive Director of the Secretary of Energy Advisory Board (SEAB), the highest-level external advisory board at the U.S Department of Energy. In the conglomerate of companies owned by the Murdock family, Pacific Holding Corp., Mr. Pernice was a member of Chairman’s global leadership team, a senior executive and officer of Dole Food Company Inc., and a senior executive for Castle & Cooke, Inc., where he managed corporate affairs and other executive level functions. He was previously a partner in the Cappello Group, a boutique investment and merchant bank in Los Angeles; a codeveloper and partner in Green Partners USA, an international real estate development fund in partnership with Goldman Sachs, the Bond Companies, and former Secretary of Energy Spencer Abraham; and has served on multiple public boards. Currently, Mr. Pernice is President of Modena Holding Corp., a strategic advisory services company that provides executive counsel to early stage and Fortune 500 companies and is a member of the Board of Directors of Trio Petroleum, Inc. and D3 Energy Corp. Mr. Pernice holds a B.A. from the University of Southern California.

Mr. Jafri is the founder and CEO of the Company’s subsidiary Immunicom, Inc., as well as President and COO of the Company. He has more than 35 years of experience in healthcare technology and devices, working in Fortune 20 companies and his own startups. In 2013, he founded Immunicom, a medical technology company focused on developing innovative, non-pharmaceutical approaches for the treatment of cancer, and inflammatory and autoimmune diseases. Previously, Mr. Jafri held executive leadership positions at West Health, CareFusion, Cardinal Health and the Manpower Group. In those capacities he has had multiple business unit responsibility for global product groups with $4B in annual revenue with over 1,500+ global employees. Currently, he serves on the board of various healthcare technology startup companies, nonprofit organizations and NASDAQ companies. He has significant experience with FDA, EU and other national regulatory agencies and has launched over 50 products around the world. Mr. Jafri has 40+ industry patents to his credit. He has founded two other healthcare technology companies that have been successfully acquired.

Mr. Hogenhuis is the CEO of the Company’s subsidiary Chimera Bioengineering, Inc. and Chief Business Officer of the Company. Mr. Hogenhuis received his MD degree from Leiden University, The Netherlands, and his MBA from the Wharton School of the University of Pennsylvania. He has had a long and distinguished career as SVP at both Merck and GSK with responsibility across diverse therapeutic areas including oncology and cell & gene therapy, with P&L management in the US, Europe and China of ~$2B in annual turnover. He advanced 6 gene therapy candidates through development, commercialization strategy, and design of a GMP plant, as COO of a biotechnology company, and has negotiated numerous business development deals throughout his career.

Raju Chauhan holds the position of COO at Immunicom, a subsidiary of the Company, and serves as Co-COO of the Company. Within Immunicom, he oversees critical functions such as manufacturing, quality control, patent portfolio management, and business operations. With over 35 years of experience in technology development, Raju has a track record of delivering innovative and cost-effective solutions for mission-critical business challenges. He has played a key role in managing large-scale projects and operations for various healthcare startups and Fortune 50 companies, including Becton-Dickinson, Cardinal Health, and CareFusion. His experience spans multiple industries, including medical device manufacturing, healthcare, oil and gas, software development, telecommunications, food and beverages, airlines, background checks, real estate, professional services, and utilities.

Raju holds a bachelor’s in engineering from G.B. Pant University in India and a master’s degree in Computer Science from Mississippi State University. Outside of work, he is an avid hiker and has tackled challenging trails such as Everest base camp, Kilimanjaro, the Grand Canyon, and the Inca Trail.

Mr. Ilkhani has been the Chief Financial Officer of the Company’s subsidiary Bryologyx and will continue in that capacity at the Company. He has more than 25 years of broad finance experience in financial management, financial/economic consulting, and corporate development. In addition to financial management and leadership roles of increasing responsibility, he has led numerous high-profile assignments in valuations (including those of pharmaceutical and healthcare assets), transactions, and sophisticated modeling for strategic planning and financial forecasting. Mr. Ilkhani received his BA from the University of California, Berkeley (with Honors), his MBA from the University of Chicago Booth, and his MSc from the University of Oxford, where his dissertation (received with Merit) was regarding healthcare economic evaluation of a CAR-T therapy.

Mr. Prince has been serving as the Chief Commercial Officer of the Company’s subsidiary Immunicom and will continue in that capacity as well as hold that position at the Company. He has 35 years healthcare technology leadership in companies ranging in size from startups to Fortune 50 and has a long history of successful global product launches. He was a co-founder of CRISII Medical Systems, acquired by Becton Dickenson in 2015. He has held prior executive roles in Sales/Marketing/Innovation/Strategy at BD, Cardinal Health, CareFusion and Gen-Probe. Mr. Prince has worked in both Europe and Asia and has significant experience in global market development for new FDA regulated technology products. Mr. Prince received his BSEE degree from Michigan Tech University, his MSEE degree from Marquette University, and his MBA from Northwestern University’s Kellogg Graduate School of Management. He holds over a dozen issued US & international patents.

Dr. Fakhrai is the inventor of Vaxanix’s lead clinical candidate Lucanix and core cancer vaccine technology. Dr. Fakhrai was one of the pioneers of immunogene cell therapy of cancer and the first to recognize the importance of blocking immuno-suppressive proteins in cancer vaccine therapy. He was also the lead scientist in the first ever treatment of a glioma patient with immunogene therapy. Dr. Fakhrai has held leadership positions in gene therapy research at the University of California, Los Angeles School of Medicine, and the Sidney Kimmel Cancer Center, among other leading centers. Dr. Fakhrai formerly served on the board of editors of Cancer Gene Therapy. He received his degree in Human Genetics from Michigan State University and performed postdoctoral fellowships in molecular biology and immunology at University of California, San Diego, and Scripps Clinic Research Foundation in La Jolla California.

Mr. Florin has been serving as the Chief Clinical Officer of Vaxanix’s Immunicom subsidiary. Mr. Florin possesses extensive clinical development experience as a founder operator of successful Site Management Organizations (SMOs), Clinical Research Organizations (CROs) and clinical technology companies. Mr. Florin has served in global leadership roles in these and sponsor companies directly overseeing clinical operations, project management patient engagement, clinical outsourcing as well as business development. Mr. Florin has led the execution and successful reporting of multiple oncology trials, including one of the largest oncology trials in NSCLC. He also has led executive consulting engagements focused on strategic program design planning from development through post-marketing and life-cycle management and other value-add activities. In addition to his considerable experience designing and leading drug and biologic, drug-device combination and device product development programs across multiple therapeutic areas (including oncology and orphan disease indications), Mr. Florin is a frequent speaker at and contributor to industry meetings and publications across a range of topics. Mr. Florin has been recognized for his efforts in leveraging technology to improve patient recruitment and retention, risk-based monitoring and overall study management—including spearheading the development and marketing of leading-edge enterprise clinical analytics and patient engagement systems.

Dr. Epstein is the Scientific Co-Founder of the Company’s subsidiary Cell BT, Inc. He is a tenured Professor at the USC Keck School of Medicine where his research focuses on the development of reagents for the immunotherapy of cancer and genetically engineered T cells for the treatment of solid tumors as part of his distinguished career in the field of tumor biology research. This research also includes elucidating the host/tumor interaction, which encompasses the induction and function of suppressor cell populations and methods to reverse their activity in cancer. He received his MD/PhD at Stanford University. Over a 34 year career he has developed several antibodies for the treatment of cancer including Lym-1 for lymphoma therapy and tumor necrosis antibodies that target necrosis n cancer lesions. In addition, he has invented the DAP 10/12 construct for use in CAR-T therapies to reduce tonic signaling and mitigate T cell exhaustion. He has founded three biotechnology companies, acted as a consultant to the industry, and led the development of an antibody product that has been approved for commercialization by the Chinese medical regulatory agency.

Dr. Shenouda has been serving as the Vice President of Regulatory Affairs of the Company’s subsidiary Immunicom, and will hold a position as Chief Clinical Officer at the Company. Prior to Immunicom, he joined from the Food and Drug Administration (FDA) where he worked in both The Center for Drug Evaluation and Research (CDER) and The Center for Devices and Radiological Health (CDRH).  He has worked as a clinician, researcher, and regulator, but has always focused on improving the lives of patients whether it be through direct patient care, clinical trial conduct, or evaluation of drug/device applications for the broad public health.  As a regulatory physician, he is responsible for the communication and implementation of strategy enabling an efficient and expedited path to market to ensure patients may avail of novel technologies. Dr. Shenouda provides regulatory strategy based on his experience in a wide range of device applications including invasive brain computer interfaces (BCI), over the counter products, software as medical device (SaMD), and novel biomarkers.  In addition to review of Premarket Approval (PMA), De Novo, 510k and Investigational Device Exemption (IDE) applications, Dr. Shenouda has worked on FDA guidance documents and served as the liaison to military and industry partners.  In conjunction with work in device evaluation, he has worked in the Office of Compliance to evaluate Good Clinical Practice (GCP) conduct and brings regulatory and inspectional insights to the conduct of clinical trials. Prior to his work at FDA, Dr. Shenouda was a supervisory medical officer at the National Institutes of Health (NIH) where he worked in the design and conduct of clinical trials for concussion/traumatic brain injury, which used advanced imaging and blood-based biomarkers. Dr. Shenouda is a dual board-certified physician with a specialization in neurorehabilitation and completed his fellowship at the University of Washington and residency/chief residency at Baylor College of Medicine in Houston, Texas.